Overview

Early Subcutaneous Insulin Glargine Plus Standard of Care for Treatment of Diabetic Ketoacidosis

Status:
Active, not recruiting
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether adult DKA patients who present to the emergency department treated with early subcutaneous long acting insulin versus standard care receive a shorter total duration of intravenous (IV) insulin infusion.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland
University of Maryland, Baltimore
Treatments:
Insulin
Insulin Glargine
Insulin, Globin Zinc